Literature DB >> 19748175

A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy.

Qunzhou Zhang1, Shihong Shi, Yun Yen, Jimmy Brown, Joseph Quoc Ta, Anh D Le.   

Abstract

The potential role of cancer stem-like cells (CSCs) in chemoresistance of human oral squamous cell carcinoma (OSCC) was examined. A small subpopulation (1-2%) of CD133(+) CSCs was identified in OSCC cell lines and tissues. These CD133(+) CSCs possess higher clonogenicity, invasiveness, and increased in vivo tumorigenicity as compared to CD133(-) counterparts. Meanwhile, CD133(+) CSCs were substantially resistant to standard chemotherapy, wherein both in vitro and in vivo treatment with paclitaxel resulted in a marked enrichment for CD133(+) CSCs. Our data suggest that CD133(+) cells represent a small subpopulation of CSCs that may contribute to chemoresistance in human OSCC. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748175     DOI: 10.1016/j.canlet.2009.08.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  92 in total

Review 1.  The biology of head and neck cancer stem cells.

Authors:  Zhaocheng Zhang; Manoel Sant'Ana Filho; Jacques E Nör
Journal:  Oral Oncol       Date:  2011-11-08       Impact factor: 5.337

Review 2.  Head and neck cancer stem cells.

Authors:  S Krishnamurthy; J E Nör
Journal:  J Dent Res       Date:  2011-09-20       Impact factor: 6.116

3.  Isolation and Characterization of Cancer Stem Cells from Primary Head and Neck Squamous Cell Carcinoma Tumors.

Authors:  Hong S Kim; Alexander T Pearson; Jacques E Nör
Journal:  Methods Mol Biol       Date:  2016

4.  Relationship between CD44high/CD133high/CD117high cancer stem cells phenotype and Cetuximab and Paclitaxel treatment response in head and neck cancer cell lines.

Authors:  Ana Livia Silva Galbiatti-Dias; Glaucia Maria Mendonça Fernandes; Marcia Maria Urbanin Castanhole-Nunes; Luiza Fernandes Hidalgo; Carlos Henrique Viesi Nascimento Filho; Rosa Sayoko Kawasaki-Oyama; Leticia Antunes Muniz Ferreira; Patricia Matos Biselli-Chicote; Érika Cristina Pavarino; Eny Maria Goloni-Bertollo
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

Review 5.  Cancer Stem Cells in Squamous Cell Carcinoma.

Authors:  Zhe Jian; Alexander Strait; Antonio Jimeno; Xiao-Jing Wang
Journal:  J Invest Dermatol       Date:  2016-11-24       Impact factor: 8.551

6.  Enrichment and characterization of cancer stem-like cells in ultra-low concentration of serum and non-adhesive culture system.

Authors:  Junfeng Zhang; Yunsheng Zhang; Lin Cheng; Chunlei Li; Lei Dai; Hui Zhang; Fenglian Yan; Hui Shi; Guanjun Dong; Zhaochen Ning; Wei Xu; Chuanping Si; Hongxin Deng; Huabao Xiong
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

7.  Targeting Notch1 and IKKα Enhanced NF-κB Activation in CD133+ Skin Cancer Stem Cells.

Authors:  Zhong Chen; Carter Van Waes; Xin Xin Quan; Nga Voong Hawk; Weiping Chen; Jamie Coupar; Steven K Lee; David W Petersen; Paul S Meltzer; Andrew Montemarano; Martin Braun
Journal:  Mol Cancer Ther       Date:  2018-06-29       Impact factor: 6.261

8.  Expression of Cancer Stem Cell Biomarkers in Human Head and Neck Carcinomas: a Systematic Review.

Authors:  Raissa Borges Curtarelli; Jussara Maria Gonçalves; Luciane Geanini Pena Dos Santos; Maria Gorete Savi; Jacques Eduardo Nör; Luis André Mendonça Mezzomo; Mabel Mariela Rodríguez Cordeiro
Journal:  Stem Cell Rev Rep       Date:  2018-12       Impact factor: 5.739

Review 9.  Perivascular stem cell niche in head and neck cancer.

Authors:  Kathryn E Ritchie; Jacques E Nör
Journal:  Cancer Lett       Date:  2012-07-25       Impact factor: 8.679

10.  Aldehyde dehydrogenase isoform 1 (ALDH1) expression as a predictor of radiosensitivity in laryngeal cancer.

Authors:  M Martín; A Hinojar; L Cerezo; J García; M Lopez; J Prada; A Marín; C Gamallo
Journal:  Clin Transl Oncol       Date:  2015-11-16       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.